Physician profile
Avi I Einzig
NPI 1245311414
$5,045.28
in general payments reported to CMS, 2019-2025
27 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $141 · 2021: $383 · 2022: $779 · 2023: $1,039 · 2024: $1,094 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.63 |
| Education | $238.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,182.54 | 2019-2025 | |
| Janssen Biotech, INC. | $857.92 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Incyte Corporation | $376.66 | 2021-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $326.26 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $264.90 | 2022-2024 | Darzalex, Imbruvica, Tecvayli |
| Celgene Corporation | $221.97 | 2022-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $212.53 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $212.17 | 2019-2024 | Tazverik, Onivyde |
| Genzyme Corporation | $181.77 | 2023-2025 | |
| Genentech USA, INC. | $142.31 | 2019 | |
| Seagen INC. | $129.04 | 2022-2023 | Adcetris |
| Astrazeneca Pharmaceuticals Lp | $106.13 | 2022-2025 | Enhertu |
| Sumitomo Pharma America, INC. | $103.76 | 2023-2025 | Orgovyx, Gemtesa |
| Kite Pharma, INC. | $98.72 | 2022-2023 | Yescarta |
| Gilead Sciences, INC. | $93.16 | 2019-2025 | Trodelvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $84.06 | 2020-2022 | |
| Glaxosmithkline, LLC. | $74.07 | 2025 | Ojjaara, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $71.38 | 2024-2025 | Opdivo, Krazati, Augtyro |
| Pharmacyclics LLC, An Abbvie Company | $69.95 | 2019 | |
| Array Biopharma INC | $45.62 | 2023-2024 | Braftovi, Lorbrena, Mektovi |
| Myovant Sciences INC. | $41.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.72 | 2023 | Ninlaro |
| Kyowa Kirin, INC. | $35.71 | 2022 | |
| Daiichi Sankyo INC. | $28.85 | 2025 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $21.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.46 | 2019 | |
| Lilly USA, LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avi Einzig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.